Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H23N3O4.ClH |
Molecular Weight | 369.843 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CN(CCNCC(O)COC2=C(C)C=CC=C2)C(=O)NC1=O
InChI
InChIKey=OOHOLIQGGQPTLN-UHFFFAOYSA-N
InChI=1S/C17H23N3O4.ClH/c1-12-5-3-4-6-15(12)24-11-14(21)9-18-7-8-20-10-13(2)16(22)19-17(20)23;/h3-6,10,14,18,21H,7-9,11H2,1-2H3,(H,19,22,23);1H
Primidolol (also known as UK-11,443) is an imidazolidinone derivative patented by American pharmaceutical corporation Pfizer Corp as a specific β-adrenergic blocker. In clinical trials, Primidolol shows some antihypertensive activity but the overall change in the cardiovascular parameters failed to demonstrate a significant difference compared to placebo.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6104564
50 mg or 100 mg daily, for a 4 days.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
40778-40-3
Created by
admin on Sat Dec 16 08:36:52 GMT 2023 , Edited by admin on Sat Dec 16 08:36:52 GMT 2023
|
PRIMARY | |||
|
QAT67NBE8Q
Created by
admin on Sat Dec 16 08:36:52 GMT 2023 , Edited by admin on Sat Dec 16 08:36:52 GMT 2023
|
PRIMARY | |||
|
176173
Created by
admin on Sat Dec 16 08:36:52 GMT 2023 , Edited by admin on Sat Dec 16 08:36:52 GMT 2023
|
PRIMARY | |||
|
DTXSID4021187
Created by
admin on Sat Dec 16 08:36:52 GMT 2023 , Edited by admin on Sat Dec 16 08:36:52 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD